Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.82 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.59 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.59 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.59 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trypan Blue Free Acid SCHEMBL15497820 | 1.00 | MEN1 (1.00) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| Trypan Blue Free Acid SCHEMBL12234090 | 1.00 | MEN1 (1.00) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| Trypan Blue Free Acid SCHEMBL29355441 | 1.00 | MEN1 (1.00) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| Trypan Blue Free Acid SCHEMBL29415031 | 1.00 | MEN1 (1.00) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| SCHEMBL13243797 | 0.97 | MEN1 (0.94) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| SCHEMBL24438814 | 0.93 | MEN1 (0.87) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| SCHEMBL18784959 | 0.92 | MEN1 (0.85) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| SCHEMBL21105389 | 0.92 | MEN1 (0.85) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| SCHEMBL20128454 | 0.92 | MEN1 (0.85) | MEN1KMT2AHTTPHLPP2ENPP2 | |
| SCHEMBL14215680 | 0.92 | MEN1 (0.85) | MEN1KMT2AHTTPHLPP2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115074325-A | Herceptin combined 4-1BBL in-vitro amplification NK method | 广州希灵生物科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| EP-4739346-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | D3 Bio(Wuxi) Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260103679-A1 | COMPOSITIONS COMPRISING REGULATORY T CELLS AND METHODS OF USING THE SAME | CELLENKOS INC (IS) | 2026-04-16 | — | — | US | disclosed |
| US-12578333-B2 | Aerosol biosensors and related aspects for pathogen detection | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260053853-A1 | ENGINEERED T CELL RECEPTOR CONSTRUCTS FOR CANCER THERAPY | HADASIT MED RES SERVICE (IL) | 2026-02-26 | — | — | US | disclosed |
| US-20260049290-A1 | HUMAN SPINAL CORD INJURY ORGANOIDS | UNIV NORTHWESTERN (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260027201-A1 | Methods of Treating Glioblastoma | EMORY UNIVERSITY (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260021181-A1 | CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333472-A1 | Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto | GEORGE MASON RES FOUNDATION INC (US) | 2025-10-30 | — | — | US | disclosed |
| CN-114430681-A | Treatment of EGFR mutation-related cancers with combinations of EGFR and CDK4/6 inhibitors | 贝达医药公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2022081452-A1 | NOVEL NR1 ES-DERIVED NEURAL STEM CELLS HAVING A NORMAL KARYOTYPE AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3980041-A1 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3976183-A1 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Janssen Biotech, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220073881-A1 | COMPOSITIONS AND METHODS FOR IMPLANTATION OF PROCESSED ADIPOSE TISSUE AND PROCESSED ADIPOSE TISSUE PRODUCTS | THE JOHNS HOPKINS UNIVERSITY | 2022-03-10 | — | — | US | disclosed |
| EP-3963050-A1 | PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS | PROMETHERA THERAPEUTICS SA (BE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3963049-A1 | PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS | PROMETHERA THERAPEUTICS SA (BE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3947645-A1 | ADULT LIVER PROGENITOR CELLS FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | PROMETHERA THERAPEUTICS SA (BE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947644-A1 | ADULT LIVER PROGENITOR CELLS FOR TREATING ACUTE-ON-CHRONIC LIVER FAILURE | PROMETHERA THERAPEUTICS SA (BE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022026495-A1 | ANTIMICROBIAL SILK NANOPARTICLES AND METHODS FOR MAKING AND USING THE SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12578333-B2 | Aerosol biosensors and related aspects for pathogen detection | ACE2, ACE, TMPRSS2 | MEN1 4732/4885KMT2A 4587/4885HTT 4424/4885 |
| US-20260103679-A1 | COMPOSITIONS COMPRISING REGULATORY T CELLS AND METHODS OF USING THE SAME | CD4, CCR9, CD2 | MEN1 4340/4885KMT2A 3334/4885HTT 3875/4885 |
| US-20250333472-A1 | Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto | SNRPE, SSBP1, RPA1 | MEN1 3891/4885KMT2A 4392/4885HTT 2693/4885 |
| US-20260049290-A1 | HUMAN SPINAL CORD INJURY ORGANOIDS | NES, SMN1; SMN2, NCDN | MEN1 3550/4885KMT2A 403/4885HTT 274/4885 |
| US-20260021181-A1 | CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES | CCR3, IL2, IL2RA | MEN1 4656/4885KMT2A 766/4885HTT 4245/4885 |
| US-20260053853-A1 | ENGINEERED T CELL RECEPTOR CONSTRUCTS FOR CANCER THERAPY | TAP1, MICA, CD74 | MEN1 3523/4885KMT2A 2719/4885HTT 2582/4885 |
| US-20260027201-A1 | Methods of Treating Glioblastoma | ICOS, IL2, CD4 | MEN1 822/4885KMT2A 1006/4885HTT 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.